News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bay Area's FibroGen, Inc. Touts Phase 2 Data For Idiopathic Pulmonary Fibrosis Drug FG-3019


5/19/2014 6:44:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FibroGen Announces Phase 2 Data Supporting Longer-Term Safety and Efficacy Profile of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis

SAN DIEGO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States. FG-3019 is an investigational monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a central mediator of fibrotic disease.

Today’s presentation focused on patients in the first cohort of a Phase 2a study of FG-3019 who completed one year of treatment as well as patients in the first cohort who continued to receive treatment for a total of two years.

Consistent with previous results, FG-3019 was well tolerated in IPF patients treated for up to two years. No serious adverse events were considered to be related to treatment with FG-3019.

The study evaluated changes in pulmonary function, changes in pulmonary fibrosis, and patient reported outcomes, a measure of overall patient quality of life. The study employed quantitative high resolution computed tomography, or HRCT, which is an accurate and reproducible method to measure changes in the percentage of the patient’s lung tissue that is fibrotic. Recent publications based on similar quantitative HRCT methods have identified an association between worsening pulmonary fibrosis and mortality in IPF.1

The study enrolled patients with a wide range of IPF severity to assess safety and efficacy across a broad spectrum of the disease. Efficacy data from patients with mild to moderate disease (n=37) were analyzed in the presentation, a patient population similar to those evaluated in other recent IPF clinical trials. Thirty-three of these patients completed 48 weeks of treatment.

After 48 weeks of treatment, twelve of the 33 patients (36%) had improved fibrosis as measured by quantitative HRCT. Prior to this finding, improved fibrosis had never been reported in IPF patients. An additional two patients had stable fibrosis for a total of 14 patients (42%) with improved or stable fibrosis.

Change in forced vital capacity, or FVC, also correlated with changes in fibrosis (p=0.005, r= -0.476) at 48 weeks. Patients with improved or stable fibrosis also had improved pulmonary function at week 48 with FVC change of +0.05 liters compared to -0.24 liters for patients with worsening fibrosis (p=0.006).

The St. George’s Respiratory Questionnaire (SGRQ) is often used in IPF trials to assess changes in patients’ perceptions of disease impact on their quality of life. Improvements in the SGRQ symptoms score correlated significantly with improvements in fibrosis at both 6 months and 12 months (p<0.05) assessments.

Eighteen of the 33 patients who completed the primary study enrolled in an extension study to continue FG-3019 treatment for a second year. Fourteen of these patients completed the second year of treatment. Four of the 14 evaluable patients experienced a prolonged improvement in pulmonary function through the second year of study, with average change in FVC from the original baseline of +0.2 liters. Six had modest decline in pulmonary function (average change from baseline after 2 year of -0.2 liters) and another 4 showed a severe decline (average change in FVC from the original baseline of -0.6 liters) at the end of the second year. Patients who experienced modest decline or improvement in FVC experienced only a modest increase in fibrosis, whereas those who experienced a severe decline also showed the greatest increase in fibrosis.

1. Maldonado et al. Eur Resp J 2014; Oda et al. Respiratory Research 2014.

Poster Information

Poster Title: Safety and Efficacy of Anti-CTGF Monoclonal Antibody FG-3019 for Treatment of Idiopathic Pulmonary Fibrosis (IPF): Results of Phase 2 Clinical Trial Two Years after Initiation

Publication Number: A1426

Poster Viewing: Sunday, May 18, 2014, Area A (Hall B2-C, Ground Level), San Diego Convention Center

About Idiopathic Pulmonary Fibrosis (IPF)
IPF is a lung disease characterized by a progressive scarring of the lungs that diminishes functional lung volume and hinders oxygen uptake. The cause of IPF is not known, and approximately two-thirds of IPF patients die within five years after diagnosis. There are currently no FDA-approved treatments for IPF. Patients are typically treated with corticosteroids and immunosuppressive agents. However, none of these agents have been clinically proven to improve survival or quality of life.

About FG-3019
FG-3019 is an investigational therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. FibroGen is currently conducting clinical studies of FG-3019 in idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FG-3019 has been well tolerated, with no apparent safety signals, in more than nine clinical studies and more than 340 treated patients to date.

About FibroGen
FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of fibrosis, anemia, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia. FibroGen is also currently pursuing the use of proprietary recombinant human type III collagens in synthetic corneas for treatment of corneal blindness. For more information please visit: www.fibrogen.com.

Contacts

FibroGen, Inc.
Greg Mann, 415-978-1433
gmann@fibrogen.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES